18 July 2025

Dr. Yansong Li Explores Immune and Coagulation Pathways in Trauma-Induced Organ Failure

Geneva-supported study advances understanding of hemorrhagic shock and multi-organ failure

Uncontrolled Hemorrhage and the Triad of Trauma

In a recent publication in the International Journal of Molecular Sciences, Dr. Yansong Li and colleagues investigated the deadly interplay between immunopathy, coagulopathy, and multi-organ failure (MOF) in traumatic hemorrhage. The study, “Impact of Immunopathy and Coagulopathy on Multi-Organ Failure and Mortality in a Lethal Porcine Model of Controlled and Uncontrolled Hemorrhage,” uses a realistic large-animal model to simulate battlefield and civilian trauma scenarios.

By combining controlled and uncontrolled bleeding in swine, the study examined the effects of fluid resuscitation using lactated Ringer’s (LR) solution versus Voluven®, a synthetic colloid. Findings revealed that while both resuscitation strategies improved short-term survival compared to no treatment, Voluven® worsened coagulopathy, kidney and liver damage, and overall outcomes, reinforcing concerns over certain resuscitation fluids in trauma care.

Targeting Early Immune Responses to Improve Outcomes

A key insight from the study was the early and sustained activation of complement, coagulation, and cytokine cascades, contributing to systemic inflammation and organ damage. These biological markers were strongly associated with lung, liver, and kidney injury, supporting the theory that immune dysfunction is not just a consequence but a driver of trauma-related organ failure.

The research underscores that coagulopathy and immunopathy are modifiable factors and potential targets for new therapies that could improve survival in severe trauma cases, especially in austere or prehospital settings where options are limited.

Supporting High-Impact Trauma Research

Geneva supports this work and others with full pre- and post-award research services, ensuring regulatory compliance, operational coordination, and scientific continuity throughout the project lifecycle.

Visit our website to learn more about Geneva’s solutions to advance military medical research in combat casualty care.